EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways

Jodie Bojko, Madhu Kollareddy, Marianna Szemes, Jacob Bellamy, Evon Poon, Ahmad Moukachar, Danny Legge, Emma E Vincent, Nicholas Jones, Sally Malik, Alexander Greenhough, Alex Paterson und 4 weitere

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jodie Bojko und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epigenetics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Protein-Arginine N-Methyltransferases, Spliceosomes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Children's Cancer and Leukaemia Group, The Little Princess Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 50 % of poor prognosis neuroblastomas arise due to MYCN over-expression. We previously demonstrated that MYCN and PRMT5 proteins interact and PRMT5 knockdown led to apoptosis of MYCN-amplified (MNA) neuroblastoma. Here we evaluate the highly selective first-in-class PRMT5 inhibitor GSK3203591 and its in vivo analogue GSK3326593 as targeted therapeutics for MNA neuroblastoma. Cell-line analyses show MYCN-dependent growth inhibition and apoptosis, with approximately 200-fold greater sensitivity of MNA neuroblastoma lines. RNA sequencing of three MNA neuroblastoma lines treated with GSK3203591 reveal deregulated MYCN transcriptional programmes and altered mRNA splicing, converging on key regulatory pathways such as DNA damage response, epitranscriptomics and cellular metabolism. Stable isotope labelling experiments in the same cell lines demonstrate that glutamine metabolism is impeded following GSK3203591 treatment, linking with disruption of the MLX/Mondo nutrient sensors via intron retention of MLX mRNA. Interestingly, glutaminase (GLS) protein decreases after GSK3203591 treatment despite unchanged transcript levels. We demonstrate that the RNA methyltransferase METTL3 and cognate reader YTHDF3 proteins are lowered following their mRNAs undergoing GSK3203591-induced splicing alterations, indicating epitranscriptomic regulation of GLS; accordingly, we observe decreases of GLS mRNA m6A methylation following GSK3203591 treatment, and decreased GLS protein following YTHDF3 knockdown. In vivo efficacy of GSK3326593 is confirmed by increased survival of Th-MYCN mice, with drug treatment triggering splicing events and protein decreases consistent with in vitro data. Together our study demonstrates the PRMT5-dependent spliceosomal vulnerability of MNA neuroblastoma and identifies the epitranscriptome and glutamine metabolism as critical determinants of this sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaN-Myc Proto-Oncogene ProteinProtein-Arginine N-MethyltransferasesSpliceosomesHumansCell Line, TumorApoptosisGene Expression Regulation, NeoplasticEpigenesis, GeneticAnimalsTranscriptomeMetabolomicsGlutaminaseMiceRNA SplicingCell Proliferation

Substanzen

N-Myc Proto-Oncogene ProteinProtein-Arginine N-MethyltransferasesMYCN protein, humanPRMT5 protein, humanGlutaminase

Autor:innen und Institutionen

  • Cancer Epigenetics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
  • Division of Clinical Studies, The Institute of Cancer Research, London, UK.
  • Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK.
  • College of Health, Science and Society, University of the West of England, Bristol, BS16 1QY, UK.
  • Insilico Consulting ltd, Wapping Wharf, Bristol, England, UK.

Förderung

  • Cancer Research UK
  • Children's Cancer and Leukaemia Group
  • The Little Princess Trust
  • Neuroblastoma Society
  • Institute of Cancer Research
  • The Institute of Cancer Research
  • Biotechnology and Biological Sciences Research Council

Zitieren

APA

Bojko, J., Kollareddy, M., Szemes, M., Bellamy, J., Poon, E., Moukachar, A., Legge, D., Vincent, E. E., Jones, N., Malik, S., Greenhough, A., Paterson, A., Park, J. H., Gallacher, K., Chesler, L., & Malik, K. (2024). Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217263

Vancouver

Bojko J, Kollareddy M, Szemes M, Bellamy J, Poon E, Moukachar A, et al. Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217263

BibTeX
@article{Bojko2024,
  author = {Bojko, Jodie and Kollareddy, Madhu and Szemes, Marianna and Bellamy, Jacob and Poon, Evon and Moukachar, Ahmad and Legge, Danny and Vincent, Emma E and Jones, Nicholas and Malik, Sally and Greenhough, Alexander and Paterson, Alex and Park, Ji Hyun and Gallacher, Kelli and Chesler, Louis and Malik, Karim},
  title = {Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217263}
}
Kostenlos starten →